Bookmark

Add to MyYahoo RSS

Myriad Genetics News

News on Myriad Genetics (Ticker: MYGN) continually updated from thousands of sources around the net.

6 hrs ago | Sys-Con Media

Company Announcements, Divestitures, Earnings Releases, and Stock...

Today, Analysts Review released its analysts' notes regarding Costco Wholesale Corporation , Liberty Media Corp. , Apollo Education Group Inc. , Yum! Brands Inc. , and Myriad Genetics Inc. .

Comment?

Related Topix: Liberty Media, Media, Television, Retail, Costco Wholesale, Yum Brands, Restaurant Management, Apollo Group, Biotech, Medicine, Healthcare Industry, Genetics

Tue Apr 22, 2014

Science Daily

New patenting guidelines needed for biotechnology

Biotechnology scientists must be aware of the broad patent landscape and push for new patent and licensing guidelines, according to a new paper.

Comment?

Related Topix: Inventions, Science / Technology, US News, US Supreme Court, Biotech, Medicine, Healthcare Industry, Genetics, Patent / Trademark Law, Law

JD Supra

Review - U.S. Patent and Trademark Office Subject Matter Eligibility Guidelines

On March 4, 2014 the USPTO issued new patent subject matter eligibility guidelines in an attempt to provide examiners and patent practitioners with some guidance on which claims improperly encompass laws of nature, natural principles, natural phenomena, or products of nature in the wake of the U.S. Supreme Court ruling in Association for Molecular ... (more)

Comment?

Related Topix: Patent / Trademark Law, Law, US News, US Supreme Court, Biotech, Medicine, Healthcare Industry, Genetics

Thu Apr 17, 2014

Investor's Business Daily

Myriad Genetics Is Saving Lives With New Products

Specialties are in vogue at many companies these days, but there's always room for diversifying products, generating revenue streams and expanding the clientele.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Biology, Science, Myriad Pharmaceuticals

Wed Apr 16, 2014

Local Tech Wire

Biotech patent holders: I hate to say I told you so, but ...

Editor's Note: Edward R. Ergenzinger, Ph.D., is a member of the Intellectual Property Practice Group at Ward and Smith, P.A. On March 4, 2014, the U.S. Patent and Trademark Office issued new guidelines to its Patent Examiners to assist them in determining which patent claims are not eligible for patenting.

Comment?

Related Topix: Patent / Trademark Law, Law, Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals, US News, US Supreme Court

Mon Apr 14, 2014

AmericanBankingNews.com

Myriad Genetics Receives Neutral Rating from Bank of America

's stock had its "neutral" rating restated by stock analysts at Bank of America in a report issued on Monday, AnalystRatings.Net reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

Sat Apr 12, 2014

Salt Lake Tribune

Led by Myriad Genetics, Utah health services make millions from Medicare

Myriad Genetics takes in twice as much revenue from Medicare - $54 million in 2012 - as all other laboratories and similar businesses in Utah combined, according to an analysis of federal data.

Comment?

Related Topix: Medicare, Health, Biotech, Medicine, Healthcare Industry, Genetics, Sundance Film Festival, Utah, Biology, Science

Wed Apr 09, 2014

The Motley Fool

The Nasdaq's 3 Most Hated Stocks

Since hitting highs not seen in practically 14 years, the technology- and biotechnology-heavy Nasdaq Composite has been throttled, falling more than 5% on a trailing basis from the high point reached in early March.

Comment?

Related Topix: Financial Markets, Biotech, Science / Technology, Home, Mortgage, Personal Finance, Medicine, Healthcare Industry, Medicare, Health

Mon Apr 07, 2014

GlobeNewswire

DGAP-News: Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis

News: Myriad Genetics, Inc. / Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis 07.04.2014 / 22:30 --------------------------------------------------------------------- BRACAnalysis to be Used as Companion Diagnostic for AstraZeneca's Olaparib SALT LAKE CITY, 2014-04-07 22:30 CEST -- Myriad Genetics, Inc. today announced that it ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

GlobeNewswire

Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis

Myriad Genetics, Inc. today announced that it has submitted the first module of a premarket approval application to the Food and Drug Administration for the use of BRAC Analysis testing as a companion diagnostic with olaparib.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

The Motley Fool

The AACR Annual Meeting May Move These 2 Stocks

The American Association for Cancer Research meeting shines a bright light on gene testing like that performed by Myriad, and on promising late stage breast cancer treatments, including Pfizer's palbociclib.

Comment?

Related Topix: Medicine, Cancer, Health, Biotech, Healthcare Industry, Breast Cancer, Genetics, Biology, Science, Startups, BioMarin Pharmaceutical

Fri Apr 04, 2014

AmericanBankingNews.com

Mizuho Upgrades Myriad Genetics to "Buy"

Several other analysts have also recently commented on the stock. Analysts at Cowen and Company raised their price target on shares of Myriad Genetics from $24.00 to $37.00 in a research note on Friday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals

Thu Apr 03, 2014

The Motley Fool

When Harsh Medicare Cuts Are Cause for Celebration

Though the cuts were harsh, they were lower than the market had been fearing, and Myriad came out on top as a result.

Comment?

Related Topix: Biotech, Healthcare Industry, Science / Technology, Inventions

Investor's Business Daily

Indexes Edge Higher; Rubicon Project Soars In Debut

The S&P 500 led the way, up 0.2%, while the Dow Jones industrial average and Nasdaq rose 0.1%.

Comment?

Related Topix: Medicaid, Health, Biotech, Medicine, Healthcare Industry

The Motley Fool

Why MannKind Corporation, Myriad Genetics, Inc., and Intuitive Surgical, Inc. are Today's 3 Best Sto

Record highs have been a daily occurrence for the markets as of late, and despite an up-and-down day, the S&P 500 wouldn't be held back from hitting new intraday marks yet again today.

Comment?

Related Topix: Startups, Intuitive Surgical, Biotech, Medicine, Healthcare Industry, Genetics, Biology, Science, Financial Markets

Wed Apr 02, 2014

TheStreet.com

Why Myriad Genetics (MYGN) Stock Hit a One-Year High Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Biology, Science, Mozilla, TheStreet

Investor's Business Daily

Myriad Gaps Up To High On Reimbursement Rate Change

Myriad surged 4.03, or 11%, to 39.18 in huge volume . The IBD 50 stock is 15% past a 34 buy point of a cup with handle it cleared Feb. 18. The Salt Lake City-based company updated its pricing for its BRAC-Analysis tests , which are used to gauge a woman's risk of developing hereditary breast or ovarian cancer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

The Motley Fool

Why Myriad Genetics, Inc. Popped Today

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Medicare, Medicaid, Health

AmericanBankingNews.com

Myriad Genetics Price Target Increased to $33.00 by Analysts at Jefferies Group

Jefferies Group's price objective indicates a potential downside of 6.12% from the company's current price.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Genetics, Rules-Based Medicine, Myriad Pharmaceuticals, Investment Banking, Financial Services, Jefferies Group, Investment Services

Barron's

Morning Movers: MannKind Doubles on FDA Recommendation; Myriad Genetics Soars on Medicare Decision

Shares of Mannkind have gained 92% to $7.70 after an FDA panel recommended approving one of its drugs .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Apollo Group, Agrium, Chemicals

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••